Amit Sachdev - 15 Nov 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Patient Officer
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
15 Nov 2021
Transactions value $
-$9,547
Form type
4
Filing time
16 Nov 2021, 15:07:33 UTC
Previous filing
19 May 2021
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$3.92K -21 -0.07% $186.78 32K 15 Nov 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$5.62K -30 -0.09% $187.48 31.9K 15 Nov 2021 Direct F1, F3, F4
holding VRTX Common Stock 882 15 Nov 2021 401(k)
holding VRTX Common Stock 15.6K 15 Nov 2021 Held in Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $186.78 (range $186.22 to $187.19).
F3 Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $187.48 (range $187.24 to $187.85).